focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 22.50
Bid: 22.00
Ask: 23.00
Change: -0.75 (-3.23%)
Spread: 1.00 (4.545%)
Open: 24.25
High: 24.50
Low: 22.50
Prev. Close: 23.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Angus Energy exceeds monthly production targets

Wed, 12th Oct 2022 14:39

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Angus Energy PLC - oil and gas development company focused on UK assets - Says that hourly throughput rates through its process plant now exceeds its October target production rate of 6 million standard cubic feet per day with well pressures holding in the high forties. Condensate production has stabilised at or around 120 barrels per day. Says side-track planning progresses with an adjustment to spud date to October 24 to 26 from October 20, 2022, in order to accommodate a potential supply chain issue.

----------

Canadian Overseas Petroleum Ltd - Calgary, Canada-based oil and gas company operating in Nigeria and US state of Wyoming - Receives gas flare approval for its operated 85% WI Barron Flats Shannon Unit, from Wyoming Oil & Gas Conservation Commission. "This is a great result as it will allow the company to manage increased gas production with associated high working pressures as the miscible bank moves in the injection patterns. In addition, our oil production from the Shannon Unit will increase as production rates have been restricted in certain wells due to these issues," says Chief Executive Arthur Millholland.

----------

Kistos PLC - London-based energy industry investor with licenses in the Netherlands - Says High Court of Justice of England & Wales approves cancellation of bonus shares issued on Monday and the credit of EUR50.0 million to the company's share premium account. Expects the court order approving the capital reduction, and a statement of capital approved by the court, to be filed with the Registrar of Companies no later than October 22.

----------

UniVision Engineering Ltd - Hong Kong-based CCTV and surveillance system company - Enters loan agreement with Webright Ventures Ltd to borrow GBP1.4 million. Says the loan will be unsecured, will have a period of three months and an interest rate of 8% per year. Around half the loan will be used as funds set aside ahead of the hearing of the winding-up petition against UniVision, which was announced back in January, and is due to be heard in court in Hong Kong on October 18. Adds that it is still working with its auditors to complete its audit and publish its annual report, after which the company's shares are expected to begin trading on London's AIM.

----------

Angle PLC - Surrey, England-based medical diagnostics company - Signs distribution agreement with Promedeus SRO to enable and support the roll out of the US Food & Drug Administration cleared and CE marked Parsortix PC1 system across the Czech Republic for its intended use in metastatic breast cancer. Says Promedeus, a part of the Vendeavour Group, a Private Equity fund with a focus on healthcare, has considerable expertise in distributing a range of advanced medical equipment into the Czech hospital and primary care markets with a track record for delivering high quality physician education and customer care. "We are pleased to enter into this agreement with Promedeus and are encouraged by the efforts that the Promedeus team has already made to understand the benefits that the Parsortix system can bring to their oncology focused customer base. They have a strong track record and local knowledge which can help support the development of a new market for Parsortix," says Founder & Chief Executive Andrew Newland.

----------

By Sophie Rose; sophierose@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
27 Feb 2020 12:42

Angle upbeat on recent Parsortix research out of Italy

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that Istituto Nazionale Tumori di Milano in Milan, Italy, has published results of work assessing the performance of its 'Parsortix' system in renal cell carcinoma (RCC), demonstrating key advantages of Parsortix.

Read more
17 Feb 2020 15:25

Angle upbeat on German research into 'Parsortix'

(Sharecast News) - Liquid biopsy company Angle announced on Monday that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of 'Parsortix' in multiple metastatic cancer types, with the main emphasis on metastatic breast cancer.

Read more
11 Feb 2020 10:51

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Read more
11 Feb 2020 07:41

Angle upbeat on research into Parsortix with melanoma patients

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that a customer, the Edith Cowan University in Perth, Western Australia, has published results of research into the use of its 'Parsortix' system with melanoma patients.

Read more
30 Jan 2020 11:41

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Read more
23 Jan 2020 16:10

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
22 Jan 2020 11:00

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Read more
7 Nov 2019 13:50

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Read more
31 Oct 2019 15:38

Angle Submits Positive Test Results For Parsortix System To US FDA

Angle Submits Positive Test Results For Parsortix System To US FDA

Read more
4 Oct 2019 15:17

Angle upbeat on patent grant for prostate cancer blood assessment

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the Queen Mary University of London (QMUL) European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.

Read more
4 Oct 2019 08:58

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Read more
4 Sep 2019 14:09

Angle Reports Positive Study Results For Parsortix System

(Alliance News) - Angle PLC on Wednesday noted positive results from a study of its Parsortix system in small cell lung cancer.Parsortix is Angle's liquid biopsy technology, meaning it

Read more
29 Aug 2019 10:57

Angle Ovarian Cancer Testing Platform Study Enrols First Patients

(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.The study

Read more
29 Aug 2019 09:12

Angle initiates main phase of ovarian cancer clinical study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.

Read more
22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.